Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Innovent diversifies pipeline with China rights to three Incyte compounds

Jennie Walters
December 21, 2018 7:28 PM UTC

Innovent Biologics Inc. (HKSE:1801) added three targets and a new modality to its pipeline following a deal for Chinese rights to three clinical cancer compounds from Incyte Corp. (NASDAQ:INCY).

The biotech will get rights in China, Hong Kong, Macau and Taiwan to develop and commercialize small molecules pemigatinib (INCB54828), itacitinib (INCB39110) and parsaclisib (INCB50465) for hematological and oncology indications. Prior to the deal, Innovent's pipeline included only antibodies...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Incyte Corp.

Innovent Biologics Inc.